Skip to main content

Table 4 Less intensive front-line therapy for young fit patient with mantle cell lymphoma

From: Paramount therapy for young and fit patients with mantle cell lymphoma: strategies for front-line therapy

Regimen Series No. Age (ys) Median (range) MIPI Low/Int/High (%) ORR (%) CR (%) mFU (ms) mPFS (ms) mOS (ms) TRM (%) Second malignancy(%)
R-CHOP Howard (2002) [20] 40 55 (31–69) na 96 48 25 16.5 na 2.5 na
R-CHOP LaCasce (2012) [26] 29 55 (< 65) 21/76/3 (IPI) na na 33 18% 3-y PFS 69% 3-y OS 31 na
R-CHOP
Vs.
CHOP
Lenz (2005) [47] 38 < 65 28/66/7 a (IPI) 94a 34a 18 NRa NRa 2a na
39 < 65 20/70/10a (IPI) 75a 7a 18 NRa NRa 0a na
R-CHOP
Vs.
VR-CAP
Robak(2015) [50] 244 66(34–82) 29/38/33 89 42 40 16.1 56.3 6 na
243 65(26–88) 31/40/29 92 53 40 30.7 NR 5 na
B-R + Ibrutinib Maddocks(2015) [48] 17 5 (untreated) na (62–72) na 94 76 na NR NR na na
R-CHOP+ Ibrutinib Younes (2014) [49] 5 na na 94 (all subtypes) 72 7.1 na na na na
  1. Abbreviations as indicated in the Table 1
  2. Note: VR-CAP rituximab, cyclophosphamide, doxorubicin, bortezomib, prednisone, B-R bendamustine and rituximab
  3. a including younger than 65 years and older than 65 years